Douglas Barthold1,2, Laura E Gibbons3,4, Zachary A Marcum1,2, Shelly L Gray1,2, C Dirk Keene5, Thomas J Grabowski6, Nadia Postupna5, Eric B Larson7,4, Paul K Crane4. 1. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, WA, USA. 2. The Plein Center for Geriatric Pharmacy Research, Education, and Outreach, School of Pharmacy, University of Washington, Seattle, WA, USA. 3. General Internal Medicine, Data Management and Statistics Core, Alzheimer's Disease Research Center, University of Washington, Seattle, WA, USA. 4. Department of Medicine, UW School of Medicine, University of Washington, Seattle, WA, USA. 5. Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, WA, USA. 6. Departments of Radiology and Neurology, UW School of Medicine, Alzheimer's Disease Research Center, University of Washington, Seattle, WA, USA. 7. Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Abstract
BACKGROUND: Diabetes is a risk factor for Alzheimer's disease and related dementias (ADRD). Epidemiologic evidence shows an association between diabetes medications and ADRD risk; cell and mouse models show diabetes medication association with AD-related neuropathologic change (ADNC). OBJECTIVE: This hypothesis-generating analysis aimed to describe autopsy-measured ADNC for individuals who used diabetes medications. METHODS: Descriptive analysis of ADNC for Adult Changes in Thought (ACT) Study autopsy cohort who used diabetes medications, including sulfonylureas, insulin, and biguanides; total N = 118. ADNC included amyloid plaque distribution (Thal phasing), neurofibrillary tangle (NFT) distribution (Braak stage), and cortical neuritic plaque density (CERAD score). We also examined quantitative measures of ADNC using the means of standardized Histelide measures of cortical PHF-tau and Aβ1-42. Adjusted analyses control for age at death, sex, education, APOE genotype, and diabetes complication severity index. RESULTS: Adjusted analyses showed no significant association between any drug class and traditional neuropathologic measures compared to nonusers of that class. In adjusted Histelide analyses, any insulin use was associated with lower mean levels of Aβ1-42 (-0.57 (CI: -1.12, -0.02)) compared to nonusers. Five years of sulfonylureas and of biguanides use was associated with lower levels of Aβ1-42 compared to nonusers (-0.15 (CI: -0.28, -0.02), -0.31 (CI: -0.54, -0.07), respectively). CONCLUSION: Some evidence exists that diabetes medications are associated with lower levels of Aβ1-42, but not traditional measures of neuropathology. Future studies are needed in larger samples to build understanding of the mechanisms between diabetes, its medications, and ADRD, and to potentially repurpose existing medications for prevention or delay of ADRD.
BACKGROUND: Diabetes is a risk factor for Alzheimer's disease and related dementias (ADRD). Epidemiologic evidence shows an association between diabetes medications and ADRD risk; cell and mouse models show diabetes medication association with AD-related neuropathologic change (ADNC). OBJECTIVE: This hypothesis-generating analysis aimed to describe autopsy-measured ADNC for individuals who used diabetes medications. METHODS: Descriptive analysis of ADNC for Adult Changes in Thought (ACT) Study autopsy cohort who used diabetes medications, including sulfonylureas, insulin, and biguanides; total N = 118. ADNC included amyloid plaque distribution (Thal phasing), neurofibrillary tangle (NFT) distribution (Braak stage), and cortical neuritic plaque density (CERAD score). We also examined quantitative measures of ADNC using the means of standardized Histelide measures of cortical PHF-tau and Aβ1-42. Adjusted analyses control for age at death, sex, education, APOE genotype, and diabetes complication severity index. RESULTS: Adjusted analyses showed no significant association between any drug class and traditional neuropathologic measures compared to nonusers of that class. In adjusted Histelide analyses, any insulin use was associated with lower mean levels of Aβ1-42 (-0.57 (CI: -1.12, -0.02)) compared to nonusers. Five years of sulfonylureas and of biguanides use was associated with lower levels of Aβ1-42 compared to nonusers (-0.15 (CI: -0.28, -0.02), -0.31 (CI: -0.54, -0.07), respectively). CONCLUSION: Some evidence exists that diabetes medications are associated with lower levels of Aβ1-42, but not traditional measures of neuropathology. Future studies are needed in larger samples to build understanding of the mechanisms between diabetes, its medications, and ADRD, and to potentially repurpose existing medications for prevention or delay of ADRD.
Authors: Suzanne Craft; Laura D Baker; Thomas J Montine; Satoshi Minoshima; G Stennis Watson; Amy Claxton; Matthew Arbuckle; Maureen Callaghan; Elaine Tsai; Stephen R Plymate; Pattie S Green; James Leverenz; Donna Cross; Brooke Gerton Journal: Arch Neurol Date: 2011-09-12
Authors: Margaret E Flanagan; Eric B Larson; Rod L Walker; C Dirk Keene; Nadia Postupna; Brenna Cholerton; Joshua A Sonnen; Sascha Dublin; Paul K Crane; Thomas J Montine Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Nadia Postupna; Christopher Dirk Keene; Paul K Crane; Luis F Gonzalez-Cuyar; Joshua A Sonnen; Jessica Hewitt; Samantha Rice; Kimberly Howard; Kathleen S Montine; Eric B Larson; Thomas J Montine Journal: J Neuropathol Exp Neurol Date: 2015-02 Impact factor: 3.685
Authors: Jeffrey F Scherrer; Joanne Salas; James S Floyd; Susan A Farr; John E Morley; Sascha Dublin Journal: Mayo Clin Proc Date: 2019-08 Impact factor: 7.616
Authors: Eric Steen; Benjamin M Terry; Enrique J Rivera; Jennifer L Cannon; Thomas R Neely; Rose Tavares; X Julia Xu; Jack R Wands; Suzanne M de la Monte Journal: J Alzheimers Dis Date: 2005-02 Impact factor: 4.472
Authors: Fernanda G De Felice; Marcelo N N Vieira; Theresa R Bomfim; Helena Decker; Pauline T Velasco; Mary P Lambert; Kirsten L Viola; Wei-Qin Zhao; Sergio T Ferreira; William L Klein Journal: Proc Natl Acad Sci U S A Date: 2009-02-02 Impact factor: 11.205